Thermo Fisher Scientific has agreed to acquire viral vector contract development and manufacturing organization (CDMO), Brammer Bio, for around $1.7bn in cash.
Owned by Ampersand Capital Partners, Brammer Bio is engaged in the clinical and commercial supply of vectors for in vivo gene therapy and ex vivo gene-modified cell therapy.
The CDMO will also provide process and analytical development and regulatory support to the major pharma and biotech clients for the development of novel medicines.
Brammer Bio employs 600 employees at its primary locations in Massachusetts and Florida.
Brammer Bio president and CEO Mark Bamforth and chief scientific officer Dr Richard Snyder said: “Brammer Bio has executed more than 100 projects to supply first-in-human gene therapy clinical trials and establish commercial-ready processes, and we’re excited to join Thermo Fisher to take our business to the next level.”
Brammer Bio operates 80,000ft² early clinical campus in Alachua of Florida. The CGMP facility has spatially segregated viral vector processing in production suites to support early phase clinical trials.
The company also operates 66,000ft² phase III and commercial CGMP viral vector manufacturing facility in Cambridge of Massachusetts.
The firm also manages 49,000ft² warehouse and distribution center in Somerville, as well as 50,000ft² facility in Lexington of Massachusetts.
In March 2016, Brammer Bio was established through a merger of Florida Biologix and Brammer Biopharmaceuticals.
Subject to customary closing conditions, the deal is expected to be completed in the second quarter of this year.
Once the deal concludes, Brammer Bio will be included in Thermo Fisher’s pharma services business, which is part of the firm’s laboratory products and services segment.
Thermo Fisher Scientific president and CEO Marc Casper said: “Gene therapy is an area of increasing focus for our customers and is fast-evolving given its potential to treat a range of genetic disorders.
“The combination of Brammer Bio’s viral vector capabilities with our GMP production expertise and proprietary bioprocessing and cell culture technologies uniquely positions us to partner with our customers to drive the evolution of this incredibly fast-growing market.”